A systematic review and meta-analysis by Liu Y et al., which included 41 trials, explored the weight-loss effects of GLP-1 agonists in non-diabetic individuals with obesity or overweight. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.